Abstract
Chimeric anti-CD20 monoclonal antibody rituximab is currently a standard component of treatment in patients with CD20-positive non-Hodgkin lymphomas and chronic lymfocytic leukemia. Rituximab is administered in combination with chemoptherapy within initial immunochemotherapy, as well as within maintenance treatment with the aim of progression-free survival and in some types of lymphomas even overall prolongation of survival.
Rituximab is currently approved for intravenous infusion only. However, based on promising clinical data, subcutaneous administration seems to be safe and effective.
The aim of this rewiev is to describe a case repost of a patient treaded with subcutaneous application of rituximab and to comment same important aspects of subcutaneous administration of rituximab compared with the exciting standard intravenous form application.